Combination of Pentoxifylline with Angiotensin Converting Enzyme Inhibitors Produces an Additional Reduction in Microalbuminuria in Hypertensive Type 2 Diabetic Patients

Harmankaya, Özlem; Seber, S.; Yilmaz, Murvet

doi:10.1081/jdi-120021159

Cited by 51 publications

(34 citation statements)

References 11 publications

(12 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It had been shown that pentoxifylline reduces urinary protein excretion in diabetic subjects, both with normal renal function [166,167] and renal insufficiency [155]. Furthermore, prospective trials have demonstrated that the addition of pentoxifylline to blockers of the RAS (ACEIs [168] and ARBs) [169] is associated with a significant reduction in urinary albumin excretion. Finally, in a previous study in patients with proteinuric primary glomerular diseases, in addition to the previously described effects on TNF-α, pentoxifylline significantly reduced urinary protein excretion, which was closely associated with a decrease in urinary MCP-1 excretion [170].…”

Section: Tnf-αmentioning

confidence: 97%

Pathogenic perspectives for the role of inflammation in diabetic nephropathy

et al. 2009

View full text Add to dashboard Cite

Diabetes and its complications have become a public health problem. One of the most important complications is diabetic nephropathy, which is nowadays the main cause of chronic renal failure. In spite of our greater understanding of this complication, the intimate mechanisms leading to the development and progression of renal injury are not well understood. New perspectives in activated innate immunity and inflammation appear to be relevant factors in the pathogenesis of diabetes. Moreover, different inflammatory molecules, including adipokines, Toll-like receptors, chemokines, adhesion molecules and pro-inflammatory cytokines, may be critical factors in the development of microvascular diabetic complications, including nephropathy. This new pathogenic perspective leads to important therapeutic considerations, with new pathogenic pathways becoming important therapeutic targets that can be translated into clinical treatments for diabetic nephropathy.

show abstract

Section: Tnf-αmentioning

confidence: 97%

Pathogenic perspectives for the role of inflammation in diabetic nephropathy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Moreover, clinical trials have shown that pentoxifylline reduces urinary protein excretion in diabetic patients with normal renal function as well as in those with renal insufficiency [128,134,135] . In addition, combination of pentoxifylline and renin-angiotensin system blockers shows an additive antiproteinuric effect [136,137] .…”

Section: Il-18 Is An Inflammatory Cytokine Recently Involvedmentioning

confidence: 99%

Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy

Luis-Rodríguez¹,

Martínez‐Castelao²,

Górriz³

et al. 2012

WJD

115

View full text Add to dashboard Cite

Diabetes mellitus and its complications are becoming one of the most important health problems in the world. Diabetic nephropathy is now the main cause of end-stage renal disease. The mechanisms leading to the development and progression of renal injury are not well known. Therefore, it is very important to find new pathogenic pathways to provide opportunities for early diagnosis and targets for novel treatments. At the present time, we know that activation of innate immunity with development of a chronic low grade inflammatory response is a recognized factor in the pathogenesis of diabetic nephropathy. Numerous experimental and clinical studies have shown the participation of different inflammatory molecules and pathways in the pathophysiology of this complication.

show abstract

“…Interestingly, a recent work demonstrated that PTF (400 mg three times a day) resulted in an equivalent antiproteinuric effect to captopril (25 mg three times a day) [28]. Finally, combination of PTF with blockers of the renin-angiotensin system [29,30] is associated with significant reduction in urinary albumin excretion. Importantly, diabetic patients under long-term treatment with angiotensin II receptor blockers who present residual albuminuria, an independent predictor of the rate of decline in the glomerular filtration rate, may obtain a beneficial additive antiproteinuric effect after administration of PTF, which is associated with a reduction of urinary TNF-α excretion [30].…”

Section: Treatment Of Dn: New Perspectivesmentioning

confidence: 94%